Jia Chi Yeo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jia Chi Yeo has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Aaron C. Tan
Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
43 shared publications - Amit Jain
Division of Medical Oncology National Cancer Centre Singapore 168583 Singapore Singapore
43 shared publications - Anders Jacobsen Skanderup
Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore
43 shared publications - Angela Maria Takano
Department of Anatomical Pathology, Singapore General Hospital, Singapore
43 shared publications - Boon-Hean Ong
National Heart Centre Singapore 7 Department of Cardiothoracic Surgery Singapore, Singapore
43 shared publications - Daniel Shao Weng Tan
Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
43 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 2 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Genomic landscape of neoadjuvant gefitinib-treated EGFR-mutated NSCLC tumors. A, Oncoprint of EGFR alterations and reported EGFR TKI resistance genes within the neoadjuvant gefitinib patient cohort. B, Estimated cancer cell proportion distributions of different NSCLC cohorts. Tumors from the TKI-resistant group comprises patients from the study by Chua and colleagues (24). C, Cancer cell proportions for a subset of the treatment-naïve and neoadjuvant gefitinib cohort, selected at random for downstream purity-matched analyses. D, Distribution of the number of cancer subclones estimated in patient-level analysis between purity-matched treatment-naïve and neoadjuvant gefitinib tumors at 50× and 250× depth WES respectively. E, Inferred phylogenetic structures of treatment-naïve (A111) and neoadjuvant gefitinib (P001) patients with NSCLC with the highest number of cancer subclones within their respective cohorts. F, Inferred phylogenetic structures of treatment-naïve (A161) and neoadjuvant gefitinib (P009) patients with NSCLC with the lowest number of cancer subclones within their respective cohorts. Only known lung adenocarcinoma (LUAD) and TKI-resistant (n = 96) genes are annotated for each clone on the tree, and the mutation burden of a given clone is represented by the relative distances between nodes.
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Genomic landscape of neoadjuvant gefitinib-treated EGFR-mutated NSCLC tumors. A, Oncoprint of EGFR alterations and reported EGFR TKI resistance genes within the neoadjuvant gefitinib patient cohort. B, Estimated cancer cell proportion distributions of different NSCLC cohorts. Tumors from the TKI-resistant group comprises patients from the study by Chua and colleagues (24). C, Cancer cell proportions for a subset of the treatment-naïve and neoadjuvant gefitinib cohort, selected at random for downstream purity-matched analyses. D, Distribution of the number of cancer subclones estimated in patient-level analysis between purity-matched treatment-naïve and neoadjuvant gefitinib tumors at 50× and 250× depth WES respectively. E, Inferred phylogenetic structures of treatment-naïve (A111) and neoadjuvant gefitinib (P001) patients with NSCLC with the highest number of cancer subclones within their respective cohorts. F, Inferred phylogenetic structures of treatment-naïve (A161) and neoadjuvant gefitinib (P009) patients with NSCLC with the lowest number of cancer subclones within their respective cohorts. Only known lung adenocarcinoma (LUAD) and TKI-resistant (n = 96) genes are annotated for each clone on the tree, and the mutation burden of a given clone is represented by the relative distances between nodes.
- Open Access
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Clinical assessments of response and outcomes to neoadjuvant gefitinib-treated EGFR-mutated NSCLC. A, Consort diagram and study workflow. Study includes the baseline PET/CT scan and treatment with gefitinib 250 mg daily for a minimum of 4 weeks, followed by posttreatment PET/CT scan and surgical resection. Multiregion WES and RNA-seq were then performed on tumor sectors for multi-omics analysis. B, Waterfall plot. Dotted line indicates PR or partial metabolic response (PMR; <30% change in baseline). C, Pathologic assessment of response. Dotted line indicates the threshold for a MPR (<10% viable tumor). D and E, Correlations of clinical measures of response. D, CT response compared with pathologic response. E, PET response compared with pathologic response.
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Clinical assessments of response and outcomes to neoadjuvant gefitinib-treated EGFR-mutated NSCLC. A, Consort diagram and study workflow. Study includes the baseline PET/CT scan and treatment with gefitinib 250 mg daily for a minimum of 4 weeks, followed by posttreatment PET/CT scan and surgical resection. Multiregion WES and RNA-seq were then performed on tumor sectors for multi-omics analysis. B, Waterfall plot. Dotted line indicates PR or partial metabolic response (PMR; <30% change in baseline). C, Pathologic assessment of response. Dotted line indicates the threshold for a MPR (<10% viable tumor). D and E, Correlations of clinical measures of response. D, CT response compared with pathologic response. E, PET response compared with pathologic response.
- Open Access
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Transcriptomic analysis of neoadjuvant gefitinib-treated EGFR-mutated NSCLC tumors. A, Top 5 enriched mSigDB “hallmark” gene pathways found in neoadjuvant gefitinib or treatment-naïve tumors in GSEA. B, T-cell inflammation GEP scores between treatment-naïve and neoadjuvant gefitinib tumors. The horizontal line demarcates the GEP cutoff score (GEP = −0.318) as previously reported by Cristescu and colleagues (23). C, Heatmap summarizing the expression levels of key immune inflammatory genes within patient tumors, as well as their corresponding tumor classification into either immuneHot or immuneCold status. D, Heatmap of immune cell types estimated by CIBERSORTx ranked by the order and direction of significance (adjusted P value) between treatment-naïve vs. neoadjuvant gefitinib cohorts. E, Boxplots of selected CIBERSORTx cell-type proportions present within treatment-naïve vs. neoadjuvant gefitinib tumors.
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Transcriptomic analysis of neoadjuvant gefitinib-treated EGFR-mutated NSCLC tumors. A, Top 5 enriched mSigDB “hallmark” gene pathways found in neoadjuvant gefitinib or treatment-naïve tumors in GSEA. B, T-cell inflammation GEP scores between treatment-naïve and neoadjuvant gefitinib tumors. The horizontal line demarcates the GEP cutoff score (GEP = −0.318) as previously reported by Cristescu and colleagues (23). C, Heatmap summarizing the expression levels of key immune inflammatory genes within patient tumors, as well as their corresponding tumor classification into either immuneHot or immuneCold status. D, Heatmap of immune cell types estimated by CIBERSORTx ranked by the order and direction of significance (adjusted P value) between treatment-naïve vs. neoadjuvant gefitinib cohorts. E, Boxplots of selected CIBERSORTx cell-type proportions present within treatment-naïve vs. neoadjuvant gefitinib tumors.
- Open Access
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Analysis of immune checkpoint and cytokine/chemokine responses in purity-matched neoadjuvant gefitinib EGFR-mutated NSCLC tumors. A and B, Boxplots of selected CIBERSORTx cell-type proportions present within purity-matched treatment-naïve vs. neoadjuvant gefitinib tumors. C, Gene expression comparison of immune checkpoint and cytokine/chemokine ligand–receptor pairs. D and E, Boxplot of gene expression levels comparing CD47–SIRPA and CD200–CD200R1 immune checkpoint pairs in treatment-naïve vs. neoadjuvant gefitinib tumors. F, Correlation of immune cell type and immune checkpoint gene expression with clinical response, including CT tumor shrinkage, SUVmax change, and pathologic response.
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Analysis of immune checkpoint and cytokine/chemokine responses in purity-matched neoadjuvant gefitinib EGFR-mutated NSCLC tumors. A and B, Boxplots of selected CIBERSORTx cell-type proportions present within purity-matched treatment-naïve vs. neoadjuvant gefitinib tumors. C, Gene expression comparison of immune checkpoint and cytokine/chemokine ligand–receptor pairs. D and E, Boxplot of gene expression levels comparing CD47–SIRPA and CD200–CD200R1 immune checkpoint pairs in treatment-naïve vs. neoadjuvant gefitinib tumors. F, Correlation of immune cell type and immune checkpoint gene expression with clinical response, including CT tumor shrinkage, SUVmax change, and pathologic response.
- Open Access
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Figure 5 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Purity-matched neoadjuvant gefitinib-treated EGFR-mutated NSCLC tumors undergo a glycolytic to oxidative phosphorylation metabolic switch. A, Top 5 enriched mSigDB “hallmark” gene pathways found in purity-matched neoadjuvant gefitinib or treatment-naïve tumors in GSEA. B, Average glycolytic or oxidative phosphorylation gene expression Z-scores in treatment-naïve vs. neoadjuvant gefitinib tumors. C, Purity-matched metabolic pathway map of differentially expressed glycolysis and oxidative phosphorylation reactions in treatment-naïve vs. neoadjuvant gefitinib tumors. D, GSEA of top 5 enriched mSigDB “hallmark” gene pathways found via DSP ROIs (PanCK+, CD3+, and CD68+ regions) in representative treatment-naïve vs. neoadjuvant gefitinib tumors. E, PanCK+ metabolic pathway map of differentially expressed glycolysis and oxidative phosphorylation reactions in representative treatment-naïve vs. neoadjuvant gefitinib tumors. FC, fold change; TCA, tricarboxylic acid.
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Purity-matched neoadjuvant gefitinib-treated EGFR-mutated NSCLC tumors undergo a glycolytic to oxidative phosphorylation metabolic switch. A, Top 5 enriched mSigDB “hallmark” gene pathways found in purity-matched neoadjuvant gefitinib or treatment-naïve tumors in GSEA. B, Average glycolytic or oxidative phosphorylation gene expression Z-scores in treatment-naïve vs. neoadjuvant gefitinib tumors. C, Purity-matched metabolic pathway map of differentially expressed glycolysis and oxidative phosphorylation reactions in treatment-naïve vs. neoadjuvant gefitinib tumors. D, GSEA of top 5 enriched mSigDB “hallmark” gene pathways found via DSP ROIs (PanCK+, CD3+, and CD68+ regions) in representative treatment-naïve vs. neoadjuvant gefitinib tumors. E, PanCK+ metabolic pathway map of differentially expressed glycolysis and oxidative phosphorylation reactions in representative treatment-naïve vs. neoadjuvant gefitinib tumors. FC, fold change; TCA, tricarboxylic acid.
- Open Access
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Supplementary Figure 11. Additional boxplots of CIBERSORTx celltype proportions comparing all tumour samples present within the treatment naïve vs. neoadjuvant gefitinib cohort.
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Supplementary Figure 11. Additional boxplots of CIBERSORTx celltype proportions comparing all tumour samples present within the treatment naïve vs. neoadjuvant gefitinib cohort.
- Open Access
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Supplementary Figure 12. Heatmap of purity-matched immune cell types estimated by CIBERSORTx ranked by the order and direction of significance (adjusted p-value) between treatment naïve vs. neoadjuvant gefitinib cohorts.
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Supplementary Figure 12. Heatmap of purity-matched immune cell types estimated by CIBERSORTx ranked by the order and direction of significance (adjusted p-value) between treatment naïve vs. neoadjuvant gefitinib cohorts.
- Open Access
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S13 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Supplementary Figure 13. Additional boxplots of CIBERSORTx celltype proportions comparing only purity-matched tumour samples present within the treatment naïve vs. neoadjuvant gefitinib cohort.
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Supplementary Figure 13. Additional boxplots of CIBERSORTx celltype proportions comparing only purity-matched tumour samples present within the treatment naïve vs. neoadjuvant gefitinib cohort.
- Open Access
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Supplementary Figure 10. Correlation plots of the tumour genomic features TMB, tumour purity, and number of tumour subclones against neoadjuvant patient clinical parameters. (A) CT tumour shrinkage (%), (B) Tumour SUVmaxChange (%), (C) Pathological response (%). The Pearson correlation coefficient between each two compared features is as presented with its corresponding p-value within the plot. Each point represents the median molecular feature value across tumour sectors from the same patient.
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Supplementary Figure 10. Correlation plots of the tumour genomic features TMB, tumour purity, and number of tumour subclones against neoadjuvant patient clinical parameters. (A) CT tumour shrinkage (%), (B) Tumour SUVmaxChange (%), (C) Pathological response (%). The Pearson correlation coefficient between each two compared features is as presented with its corresponding p-value within the plot. Each point represents the median molecular feature value across tumour sectors from the same patient.
- Open Access
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Supplementary Table 6. Normalized LogCPM counts of expressed genes in Treatment Naive and Neoadjuvant Gefitinib tumours (All-samples and Purity-matched)
- 26 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer
Supplementary Table 6. Normalized LogCPM counts of expressed genes in Treatment Naive and Neoadjuvant Gefitinib tumours (All-samples and Purity-matched)